Comparison of molecular subtypes between primary breast cancer and itsmetastatic auxiliary lymph node(s)
الباحث الأول:
Binan Adil Alaaragy
الباحثين الآخرين:
Iftikhar Altemimi2, Yassir Alaa Shubbar3, Kaswer Musa Alturaihi4, Haider Rabee5
المجلة:
Annals of Tropical Medicine & Public Health
تاريخ النشر:
22 أغسطس، 2020
مختصر البحث:
Breast carcinoma primary tumors and synchronous axillaries lymph node(s) metastases may represent different
malignant clones, although the daily clinical practice depends only on the molecular subtypes of primary tumor
to select the adjuvant syste…
Breast carcinoma primary tumors and synchronous axillaries lymph node(s) metastases may represent different
malignant clones, although the daily clinical practice depends only on the molecular subtypes of primary tumor
to select the adjuvant systemic treatment. In some instances the absence of primary tumor or presence of
technical difficulties that prevent the identification of exact tumor subtypes in the primary mass mandate
seeking for alternative to test. Aim: this paper aims to compare of molecular subtypes between primary tumor
&metastatic lymph node(s). Method In this prospective cohort study, 50 patients with node positive breast
carcinoma included. Immunohistochemical analysis by using Envision method for detection of biomarkers: ER,
PR, Her2/neu and Ki-67 to determine the four molecular subtype then comparison between the primary tumor
and its metastatic lymph node(s). Results: In this study there was 22 (44%) cases with luminal-A molecular
subtype in both mass and lymph node, 21 (42%) cases with luminal-B in primary mass in comparison to 18
(36%) cases in their metastatic node, 3(6%) cases with Her2/neu enriched in the primary mass in comparison to
6(12%) cases in its metastatic node. There was 4 (8%) cases with triple negative molecular subtype which had
no difference between them.. In Conclusions: There is no statistically significant difference between primary
tumor and its metastatic lymph node(s) this concordance regarding the molecular subtypes may answer the
question that pathologist can depends on the result of molecular subtypes on lymph node with good certainty if
cannot do it on the primary tumor.
